[Leukocytapheresis for ulcerative colitis].
Leukocytapheresis(LCAP) and Granulocytapheresis(GCAP) are classified as extracorporeal circulation therapy(ECCT). These therapies are a novel, effective way to treat patients with ulcerative colitis(UC). During 7 weeks of intensive therapy(LCAP weekly, predonisolone(PSL) 30-80 mg/day), UC patients treated with LCAP revealed significant improvements on their subjective and objective symptoms compared to patients treated with PSL intravenous administration. Moreover, LCAP has been recognized as safer than other drugs for UC. In our previous study, only 9.9% out of 1,978 LCAP sessions showed some side effects, and most were mild and temporary. Therefore, LCAP could be the first choice to treat UC patients who resist and/or reveal severe complications against ordinary drug therapies.
Fukunaga
K
K
Department of Internal Medicine IV, Hyogo College of Medicine.
Sawada
K
K
Chikano
S
S
Ohnishi
K
K
Egashira
A
A
Tanaka
J
J
Nagase
K
K
Satomi
M
M
Shimoyama
T
T
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003093:Colitis, Ulcerative / Q000628:therapy*; D006801:Humans; D007937:Leukapheresis / Q000379:methods; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D011788:Quality of Life
D000893:Anti-Inflammatory Agents; D011239:Prednisolone